Rethinking postpartum depression: Protein biomarker discovery making a difference to maternal mental health
/Postpartum depression (PPD) affects 1 in 5 mothers globally and is a leading cause of maternal death—yet there’s still no reliable clinical test to identify those at risk. Current screening relies on self-reported questionnaires, which often miss or misdiagnose many women.
Ketim Technologies is changing that by developing the world’s first blood-based diagnostic test for PPD. By analysing protein biomarkers with support from AGRF and Olink proteomics, they aim to bring objective, early detection into maternal mental health care.
Driven by both science and lived experience, CEO Clarissa Yates is leading this breakthrough initiative to ensure more mothers get timely, accurate support—transforming care for families, clinicians, and communities alike.
Read More